Approximately 50% of melanomas depend on mutant B-RAF for proliferation, metastasis and survival. The inhibition of oncogenic B-RAF with highly targeted compounds has produced remarkable albeit short-lived clinical responses in B-RAF mutant melanoma patients. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to B-RAF inhibitors, and the identification of B-RAF targets may provide new strategies for managing melanoma. Oncogenic B-RAF V600E is known to promote the stabilizing phosphorylation of the anti-apoptotic protein Mcl-1, implicated in melanoma survival and chemoresistance. We now show that B-RAF V600E signaling also induces the transcription of Mcl-1 in melanocytes and melanoma. We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAF V600E activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation. Consequently, suppression of STAT3 activity disrupted B-RAF V600E -mediated induction of Mcl-1 and reduced melanoma cell survival. We propose that STAT3 has a central role in the survival and contributes to chemoresistance of B-RAF V600E melanoma.
INTRODUCTION
Cutaneous melanoma is the major cause of skin cancer-related deaths, 1 with survival rates averaging o6months for patients with metastases in visceral organs. 2 The resistance of melanoma tumor cells to cytotoxicity is largely attributed to an imbalance in apoptotic regulators. In particular, increased levels of the antiapoptotic proteins survivin, Bcl-2, Mcl-1 and Bcl-XL occur frequently in melanoma and are associated with melanoma progression. [3] [4] [5] [6] Moreover, overexpression of Mcl-1 may contribute to the acquisition of resistance to a new suite of therapies targeting the mitogen-activated protein kinases (MAPKs) B-RAF and MEK. 7, 8 B-RAF is activated by mutation in B50% of melanomas, 9 and drugs targeting oncogenic B-RAF V600 mutants show activity in treating patients with metastatic melanoma. [10] [11] [12] Oncogenic B-RAF signaling promotes the phosphorylation and stabilization of Mcl-1, which induces melanoma cell survival 13 and chemoresistance. 4, 5, 14, 15 Accordingly, the combined use of the B-RAF V600E and Mcl-1 inhibitors, PLX4032 and ABT-737, respectively, greatly enhanced the cytotoxic effect of each drug alone in melanoma cell lines. 16 In this report, we show that oncogenic B-RAF also promotes the transcriptional upregulation of Mcl-1. We have identified the signal transducer and activator of transcription 3 (STAT3) as the transcription factor regulating Mcl-1 transcription in response to oncogenic B-RAF signaling. STAT3 activity contributes to cell proliferation, cell survival, immune response evasion and angiogenesis (reviewed in Aggarwal et al, 17 Kortylewski et al 18 ) and increases with melanoma progression. 4, 18, 19 STAT3 is an established phosphorylation target of receptor-associated kinases, such as the epidermal growth factor receptor (EGFR) 20 and platelet-derived growth factor receptor (PDGFR). 21 In response to cytokines and growth factors, STAT3 phosphorylation promotes its dimerization, nuclear translocation and transcriptional functions. Phosphorylation of tyrosine-705 is required for STAT3 dimerization and phosphorylation at serine-727 can enhance STAT3 transcriptional activity (reviewed in Levy et al 22 ) . It has been established that the MAPK cascade promotes STAT3 phosphorylation at serine-727, 22 and we now show that STAT3 tyrosine-705 phosphorylation is also driven by B-RAF V600E signaling.
Our data establish that STAT3 is a central regulator of B-RAF V600E -mediated Mcl-1 transcription and melanoma cell survival and suggest that STAT3 reactivation may have a role in melanoma resistance to MAPK inhibition. In recent years, a number of molecules targeting and inhibiting the STAT3 transcription factor have been developed and have shown efficiency in vitro, 23, 24 providing a potential rational path for therapeutic exploration with MAPK inhibitors in patients with B-RAF mutant melanoma.
RESULTS

B-RAF
V600E -Mcl-1 signaling is critical for melanoma cell survival
To evaluate oncogenic B-RAF effectors, the melanoma-associated B-RAF V600E mutant was stably introduced into primary human melanocytes. As expected from previous studies, expression of oncogenic B-RAF inhibited cell proliferation, reduced the substrate-adhesion of melanocytes and prevented anoikis, a form of programmed cell death associated with loss of substrate-1 adhesion. 25, 26 B-RAF V600E signaling also increased transcript levels of the survival protein Mcl-1, as shown in whole genome transcription arrays and confirmed by qRT-PCR analyses ( Figure 1a ) and this coincided with increased Mcl-1 protein levels ( Figure 1b) .
To establish the relative contribution of Mcl-1 on the antiapoptotic functions of B-RAF V600E , we generated two highly specific Mcl-1 silencing molecules. We demonstrate that melanocytes lacking Mcl-1 underwent cell death via anoikis in response to B-RAF V600E , whereas Mcl-1-intact melanocytes survived in suspension (Figures 2a, b) . Moreover, silencing of Mcl-1 expression in melanoma cell lines, dependent on endogenous B-RAF V600E for survival, cooperated with the MEK inhibitor AZD6244 to promote apoptosis and this was opposed by caspase inhibition. This cooperative effect was associated with increased expression of the pro-apoptotic protein Bim EL by AZD6244, whereas no significant changes in the expression of the anti-apoptotic protein Bcl-2 were observed. These data are presented for NM176 cells in Figures 3a-d .
Signal transducer and activator of transcription 3 (STAT3) is activated by B-RAF
V600E
To establish the mechanisms of B-RAF-mediated Mcl-1 transcription, we applied MetaCore (GeneGo, Inc (http://portal.genego. com/cgi/data_manager.cgi)) transcription factor modeling and identified the STAT3 transcription factor as the most likely regulator of Mcl-1 expression. Mcl-1 is an established transcriptional target of STAT3 (reviewed in Aggarwal et al, 17 Liu et al 27 ), and 52 of the 1221 genes differentially expressed (P-valueo0.001) in melanocytes expressing B-RAF V600E were established STAT3 targets (Table 1) .
We subsequently confirmed that B-RAF V600E promoted the activating phosphorylation of STAT3 on both serine-727 and tyrosine-705 in human melanocytes (Figure 4a ). To examine whether the impact of B-RAF V600E on STAT3 phosphorylation was dependent on MAPK signaling, we inhibited the downstream kinase MEK with AZD6244. As shown in Figure 4b, single STAT consensus site, was potently induced by B-RAF V600E . In contrast, the Mcl-1 promoter was unresponsive to oncogenic B-RAF when the STAT3 consensus site was mutated ( Figure 5) . Further, the suppression of STAT3, using the specific inhibitor S31-201 at 100 mM (S31-201 IC 50 for STAT3 is 86 mM 28 ) (Figure 6a ) or specific STAT3 silencing (Figure 6c ), diminished Mcl-1 protein accumulation in melanocytes expressing B-RAF V600E . Importantly, these STAT3-depleted melanocytes behaved as their Mcl-1-null counterparts and showed loss of substrate adhesion associated with significant evidence of cell death (Figures 6b, d ). These data confirm that in oncogenic B-RAF V600E expressing melanocytic cells, STAT3 is activated and induces Mcl-1 expression to promote survival.
B-RAF induces expression and excretion of Il6 to activate STAT3
The downstream B-RAF kinase, ERK is known to phosphorylate STAT3 at serine-727, 22 however it was surprising to find that oncogenic B-RAF V600E signaling also promoted tyrosine-705 phosphorylation of STAT3. Therefore, we screened our transcriptome data for the B-RAF V600E -dependent regulation of candidate genes implicated in STAT Y705 phosphorylation. We found that the expression of c-SRC, which phosphorylates the Y705 residue of STAT3, 14, 29, 30 is enhanced by B-RAF V600E (2.3±0.5-fold increase in c-SRC transcript in response to B-RAF V600E ). To test the role of c-SRC in STAT3
Y705 phosphorylation, we used the inhibitor dasatinib. Dasatinib is known to inhibit c-SRC, which is frequently activated in melanoma cells, at B3 nM. 31 When B-RAF phosphorylation. STAT3 Y705 phosphorylation may also emanate from autocrine IL-6/JAK signaling 32 as our gene expression data revealed 9.5 ± 0.4-fold increase in IL-6 expression and this was confirmed at the protein level ( Figure 7b ). To test the role of autocrine IL6, conditioned media harvested from BRAF V600E -or control-transduced melanocytes was added to normal melanocytes either in the presence of control or inhibitory antibodies to IL6 or the IL6 receptor. Increased p-STAT3 Y705 was evident only in melanocytes treated for 12 h with conditioned media derived from B-RAF V600E -transduced melanocyte cultures, and this increase was reduced in the presence of IL6 inhibitory antibodies ( Figure 7b ). It is worth noting that longer exposure to conditioned media limited the effect of IL6 inhibitory antibodies presumably due to protein instability (data not shown) and 12 h was not sufficient to detect STAT3-mediated Mcl-1 protein induction (Figure 7b) prevents anoikis, a form of programmed cell death associated with loss of substrate-adhesion. 25 Oncogenic B-RAF/ERK signaling is known to promote the phosphorylation and stabilization of the anti-apoptotic protein Mcl-1 to prevent anoikis. 13 In ) and B-RAF inhibition may release feedback regulations that allow mutant PDGFRA to enhance STAT3 activation in these cells in the absence of B-RAF/MEK/ERK signaling.
As expected, the B-RAF-mediated effects on STAT3 activation require MAPK signaling, as inhibition of MEK correlates with reduced STAT3 phosphorylation in melanocytes. We propose that oncogenic B-RAF signaling cooperates with additional pathways to promote STAT3 Y705 phosphorylation. For instance, c-SRC, which phosphorylates the tyrosine 705 residue of STAT3 14, 29, 30 is highly expressed in human melanocytes compared with that in dermal fibroblasts and commonly activated in melanoma. 14, 37 Our data confirmed that c-SRC expression is induced by B-RAF
V600E
, and inhibition of c-SRC with dasatanib diminished oncogenic B-RAFmediated STAT3
Y705 phosphorylation. The concentration of dasatinib required to reduce STAT3 Y705 phosphorylation corresponded with its c-SRC inhibitory dose and was below concentrations of dasatinib required to inhibit various tyrosine receptor kinases (for example, cKit and epidermal growth factor receptor; IC 50 10-200 nM) . These data suggest that c-SRC participates in the phosphorylation of STAT3 at tyrosine-705 in B-RAF V600E -expressing melanocytes. STAT3 Y705 phosphorylation may also be induced by autocrine IL-6/JAK signaling as B-RAF V600E induced IL6 expression in melanocytes and IL-6 is an established autocrine activator of STAT3 in lung cancer. 32 We confirm that IL6 is secreted by melanocytes expressing oncogenic B-RAF and that it promotes STAT3 Y705 phosphorylation. STAT3 is an important melanoma oncogene and increased levels of phosphorylated, nuclear STAT3 occur frequently during progression from primary to metastatic melanoma. 4, 18, 19 Our data show that activated STAT3 is almost twice as common in metastatic melanomas expressing oncogenic mutant B-RAF compared with wild-type BRAF melanomas. These data are in line with a previous report demonstrating 41% p-STAT3 Y705 positivity in melanoma lymph node metastasis. 
B-RAF activates STAT3 TM Becker et al
It is likely that STAT3 contributes to some of the clinical features associated with B-RAF-dependent melanomas and their response to targeted therapy. For instance, both oncogenic B-RAF V600E and STAT3 promote melanoma brain metastases and the inhibition of STAT3 or B-RAF inhibited the progression of brain metastases. [38] [39] [40] Furthermore, infiltration of human melanoma tumors by CD4-and CD8-positive lymphocytes was induced by treatment with B-RAF inhibitors, 41 and this effect could conceivably involve the inhibition of STAT3, an established repressor of immune response. [42] [43] [44] These biological links between B-RAF and STAT3 require further investigation.
We did not stain for Mcl-1 in our melanoma cohort, because Mcl-1 is highly expressed in benign and advanced melanocytic lesions, 4 and transcriptome analyses of the 90 melanoma metastases analyzed in this study confirmed consistently high Mcl-1 transcript levels (data not shown). This is expected as Mcl-1 has a pivotal role in the survival of melanoma cells, and its induction in B-RAF wild-type melanomas may involve STAT3-independent mechanisms including PI3K activity, p38 signaling or HIF1-a function (reviewed in Akgul 45 ). In summary, we have identified a novel B-RAF/STAT3/Mcl1 signaling cascade that is vital for melanocyte and melanoma cell survival. Importantly, STAT3 can be readily targeted with small inhibiting molecules 23, [46] [47] [48] and such molecules were successfully tested in melanoma tissue culture 24 and animal models. [49] [50] [51] Thus, STAT3 may be a promising target for therapy as initial phase I clinical trials suggest tolerable toxicity and inhibition of STAT3 activity in vivo associated with responses in solid tumors (including three melanomas) and lymphoid malignancies. 52 Interestingly, recent system biology analysis of phosphoproteomic changes in B-RAF V600E mutant melanoma cell lines implicated STAT3 activation as central to vemurafenib resistance of melanoma cells 53 suggesting that re-establishment of STAT3 activity may have a critical step in MAPK inhibitor resistance, and this indicates that combination of STAT3 and MAPK inhibitors may be an effective second-line therapy.
MATERIALS AND METHODS
Cell culture and lentiviral transduction
Primary human dermal melanocytes (Cell Applications, San Diego, CA, USA) were cultured as previously described. 54 WMM1175, NM39, WMM1215, NM182, ME1042, MM200, NM112 and MelRMu melanoma cell lines and U2OS osteosarcoma cells were cultured in DMEM media with 10% FCS. WMM1175 expresses the oncogenic N-RAS G13R mutation, NM39 carries the B-RAF V600E together with a H-RAS Q61K mutation, WMM1215 cells express B-RAF V600E and an activating PDGFRA D842V mutation. All other melanoma cell lines used in these experiments carry the B-RAF V600E mutation but no other mutations in MAP kinases or signaling pathways, as determined by oncocarta somatic mutation profiling (Sequenom, San Diego, CA, USA) (data not shown). Lentiviral particles were generated and used to transduce melanocytes with Myc-tagged B-RAF V600E or copGFP control or knockdown shRNA molecules as reported previously. 33, 54 The V600E-specific B-RAF shRNA sequence corresponds to nucleotides 1853-1871 (NM_004333). The Mcl-1#1 and Mcl1#2 shRNA sequences correspond to nucleotides 952-973 and 1037-1055, respectively (NM_021960.3). The STAT3 shRNA sequence corresponds to nucleotides 1063-1081 (NM_139276). All shRNAs were cloned into the pSIH-H1-EF1-copGFP lentiviral vector (System Biosciences, Mountain View, CA, USA). The non-silencing negative control shRNA did not have considerable homology to any known human transcript and had the following sequence 5 0 -TTAGAGGCGAGCAAGACTA-3 0 . For condition media collection, the media was replaced on transduced melanocytes 1 day post transduction and then harvested 3 days post transduction. Cells and debris were removed by spinning for 5 min at 1500 r.p.m. before adding the supernatant to untransduced melanocytes. qRT-PCR Total RNA was extracted from transduced melanocytes using TRI Reagent (Sigma-Aldrich). Samples were collected from three separate experiments, and each sample was amplified twice in duplicate. 1 mg RNA was used for cDNA synthesis using SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) with an oligo(dT) 20 primer. qRT-PCR products were amplified in 25 ml from 2 ml cDNA (Power SYBR-Green PCR Master Mix, Applied Biosystems, Warrington, UK) using a Corbett Rotorgene3000 (Corbett Research, Mortlake, New South Wales, Australia) and 0. 
Gene expression arrays
Gene expression arrays of primary human dermal melanocytes lentivirally tranduced to express B-RAF V600E for 3 days using the Sentrix HumanRef-6 v.3.0 Expression BeadChip (Illumina, San Diego, CA, USA) were analyzed as follows. Average signal intensities were background subtracted and normalized using the cubic spline function in GenomeStudio and the Illumina Custom function was used to assign a differential expression score and P-value to each gene. Transcripts with detection and differential expression Po0.01 were considered significantly different. Data sets were normalized (B-RAF versus copGFP control expressing samples) and the resulting data set was analyzed with the Metacore Pathway Analysis and Data Mining for Gene Expression software, version 6.8 transcription factor modeling function.
Promoter reporter assays
The Mcl-1 promoter ( À 295 þ 25), was amplified by RT-PCR from total RNA derived from NM39 melanoma cells using the primers forward: 5 0 -AAG ACTGTTGTTCCCATCC-3 0 and reverse: 5 0 -TATAAGCTTCTGGAAGGAAGCG GAAGT-3 0 and cleaved with XhoI and HindIII. The PCR product was also used to derive the 'short' Mcl-1 promoter fragment (bases À140 to þ 25) by PvuII and HindIII restriction digest. Both fragments were inserted into the pGL3-basic vector into the HindIII and XhoI or SmaI sites respectively (Promega, Madison, WI, USA). The STAT3 consensus site (base À 94 to À 84) was inactivated by mutagenesis (TT at À 92 and À 91 to CC) in the long and the short Mcl-1 promoter constructs and the mutant primer 5 0 -CCCTTTCCCCTTCCATGGGAATACTTT-3 0 using the QuikChange mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The complete sequence of all clones was confirmed by capillary sequencing. Promoter reporter assays were performed in U2OS osteosarcoma melanoma cells. In all, 1 Â 10 5 cells were transfected with 1 mg of B-RAF
V600E
, cloned into the pCDH-CMVMCS-EF1-copGFP vector, or vector alone, together with 0.5 mg promoter plasmid. Cells were harvested 48 hours post transfection and lysed in GalactoStar lysis buffer and luciferase activity measured (Promega substrate). Promoter luciferase activity was normalized for transfection efficiency (percent of GFP-expressing cells) and presented as a fold change relative to vectortransfected cells.
Immunohistochemistry (IHC)
Melanomas tissue arrays were dewaxed before they were rehydrated with decreasing ethanol concentrations. Antigen retrieval was performed by microwaving for 12 min in 1 mM EDTA (pH 8.0) and slow cooling to room temperature over 20 min. After blocking endogenous peroxidase with 3% hydrogen peroxide in water, the slides were incubated with rabbit antip-STAT3 Y705 antibody (D3A7; Cell Signaling) diluted 1:200 overnight at 4 1C then washed with Tris-buffered saline containing 0.1% Tween20. Subsequently, the slides were incubated with biotinylated anti-rabbit antibody (E0432, Dako, Glostrup, Denmark) for 1 h at room temperature, then washed with Tris-buffered saline containing 0.1% Tween20, incubated in streptavidin-HRP (K0690; Dako) for a further 1 h at room temperature, and placed in 3,3 0 -diaminobenzidine substrate for 10-15 min (Dako). The sections were counterstained with AzureB (Sigma-Aldrich) to convert melanin into a green-purple pigment to avoid confusion with diaminobenzidine substrate. Slides were stained in 1% Azure B in water for 4 min, before being washed in running water for 5 min and dehydrated by washing in 70% ethanol for 30 s, 95% ethanol for 40 s, 95% ethanol for 50 s and two changes of 100% ethanol for 1 min each. Slides were then washed in histolene for 2 min before being mounted. Two researchers performed evaluation of the staining in a blinded manner independently. Sections were scored for staining intensity as 0 (equal to no primary control), 1 (weak positive), 2 (positive) and 3 (strong positive) and the proportion of tumor tissue with positive staining as 0 (none), 1 (o10%), 2 (o50%) and 3 (450%). Both scores were multiplied for the final positivity score.
